This is an information page only. Mounjaro (tirzepatide) is a prescription-only medicine. Free Muscle does not sell, supply, source or broker Mounjaro, tirzepatide or any product described as a "Mounjaro pill", tablet or capsule, and nothing on this page offers one. Mounjaro can only be obtained with a prescription and is dispensed by a registered pharmacy (in Great Britain, one registered with the General Pharmaceutical Council, GPhC). Mounjaro is a registered trade mark of Eli Lilly, which has no connection with this website.

This page explains whether a Mounjaro pill exists, which licensed tablets act on the GLP-1 receptor and how to recognise fake products, using the regulator, NHS and journal records listed under Sources (checked on 5 October 2026).

Key facts

• There is no Mounjaro pill: on 5 October 2026 tirzepatide was authorised in the UK, the EU and the US only as a solution for injection under the skin.
• Anything sold as "Mounjaro pills", tablets, capsules or "oral tirzepatide" is unlicensed in the UK: it is not Mounjaro, and the Medicines and Healthcare products Regulatory Agency (MHRA) has not assessed its safety, quality or effectiveness.
• The licensed tablets that act on the GLP-1 receptor do not contain tirzepatide: in the UK they include Rybelsus (semaglutide, type 2 diabetes), Wegovy tablets (semaglutide, weight management, approved 11 June 2026) and Foundayo (orforglipron, weight management and type 2 diabetes, authorised 10 August 2026).
• All of these are prescription-only; neither weight-management tablet was available on the NHS when approved, and the National Institute for Health and Care Excellence (NICE) expects to publish its orforglipron appraisal on 27 January 2027.
• On the NHS in England, Mounjaro injections are prescribed within NICE recommendations: TA1026 for overweight and obesity (being introduced in phases) and, for type 2 diabetes, TA924 and NICE guideline NG28 (updated 18 February 2026), which says tirzepatide can be considered earlier in treatment for some adults, such as those living with obesity.
• Mounjaro and the contraceptive pill: the MHRA advises that Mounjaro may reduce the effectiveness of oral contraceptives in people who are overweight, so extra non-oral contraception is advised at certain times.
• The only lawful route is a prescription, dispensed by a registered pharmacy; the MHRA says that if you are offered a GLP-1 medicine without a prescription, walk away.

Is there a Mounjaro pill or tablet?

No. As of 5 October 2026 no oral form of tirzepatide held a marketing authorisation in the United Kingdom, the European Union or the United States, according to the records below.

What the official product records list

• UK regulator: the MHRA Products database lists tirzepatide only as Mounjaro solution for injection, in pre-filled pens (including the KwikPen) or in vials. It lists no tablet, capsule or other oral form.
• UK product information: the electronic medicines compendium (emc) lists tirzepatide only as Mounjaro KwikPen solution for injection in a pre-filled pen, in six strengths from 2.5 mg to 15 mg. The UK Summary of Product Characteristics (SmPC) was last revised on 29 August 2026.
• EU: the European Medicines Agency (EMA) overview states that Mounjaro is given by injection using prefilled pens, once a week, under the skin. EMA's September 2026 list of new medicines under evaluation (data extracted 4 September 2026) includes an application for orforglipron (and generic or hybrid semaglutide applications) but none for tirzepatide, and its monthly lists of extension applications (such as a new pharmaceutical form, the route Wegovy tablets took), published up to the period ending 20 August 2026, contain none for Mounjaro.
• US: the Drugs@FDA database lists both tirzepatide products, Mounjaro and Zepbound, only as a solution for subcutaneous injection.

Unapproved compounded semaglutide and tirzepatide products

Some US compounding pharmacies have sold unapproved versions of semaglutide and tirzepatide. A review of compounding websites searched in February and March 2025 (Belcourt and colleagues, Annals of Pharmacotherapy, 2026) identified 33 unique semaglutide and/or tirzepatide products that differed from approved ones in strength, route of administration or formulation; two thirds contained semaglutide and one third tirzepatide. The 17 single-ingredient products were sublingual (under the tongue) or orally disintegrating tablet formulations, and the authors found the efficacy and safety of these compounded products largely unknown. The US Food and Drug Administration (FDA) warns that unapproved versions of semaglutide and tirzepatide do not undergo its review for safety, effectiveness and quality before they are marketed.

What research exists on oral tirzepatide

Published research on an oral form of tirzepatide is at an early stage. A PubMed title search on 5 October 2026 found only two studies of an oral tirzepatide formulation, neither in people:

• Im and colleagues (Pharmaceutics, 2026) developed an experimental tirzepatide tablet with the absorption enhancer sodium caprate and tested it in cell studies, rats (preliminary screening) and beagle dogs.
• Zhang and colleagues (Journal of Extracellular Biology, 2025) loaded tirzepatide into milk-derived vesicles and gave it by mouth to diabetic mice.

ClinicalTrials.gov lists one small early-phase study that included an experimental tirzepatide formulation: NCT06648031, a phase 1b study in Australia sponsored by Lexaria Bioscience, with 148 participants across five arms, one of them labelled "DehydraTECH Tirzepatide" (the other arms are listed as oral capsules; the registry does not state the route for this arm). It was completed in July 2025, and no results had been posted when the registry was checked.

Why Mounjaro is an injection, not a pill

Mounjaro acts on two hormone receptors, GIP and GLP-1; the EMA overview explains that this increases the insulin the pancreas releases in response to food, helps lower blood glucose in type 2 diabetes and reduces appetite. Tirzepatide itself is a peptide: the UK SmPC describes it as an amino acid sequence with a C20 fatty diacid moiety that enables binding to albumin in the blood and prolongs its half-life. After injection under the skin, about 80 per cent of the dose reaches the bloodstream (its absolute bioavailability).

Swallowed peptides face a different fate. The same SmPC notes, in its breast-feeding section, that because tirzepatide is an amino acid sequence, any small amount in breast milk "is expected to be degraded and not orally absorbed as intact drug" by the baby. The 2026 tablet study above names the obstacles to an oral version: poor gut permeability, pH-dependent solubility and the manufacturing challenges of high-dose absorption enhancers.

Oral semaglutide shows the difficulty: although its tablets contain an absorption enhancer (salcaprozate sodium), the current Rybelsus and Wegovy tablets SmPCs put its absolute bioavailability at approximately 1 to 2 per cent, with high variability between people. Orforglipron is different: a small, non-peptide molecule whose product information carries no food or water restrictions.

Licensed tablets that act on the GLP-1 receptor (none is Mounjaro)

The prescription-only tablets below are not Mounjaro: each acts on the GLP-1 receptor, none contains tirzepatide, and whether any of them suits a particular person is a decision for a prescriber.

Rybelsus (oral semaglutide)

Rybelsus is semaglutide in a once-daily tablet. Its UK SmPC (text revised March 2026) licenses it only for adults with insufficiently controlled type 2 diabetes, as an adjunct to diet and exercise; it has no weight-management indication.

Wegovy tablets (oral semaglutide)

On 11 June 2026 the MHRA approved semaglutide tablets under the Wegovy brand, describing them as the UK's first GLP-1 receptor agonist tablet for weight loss and weight management. The UK SmPC licenses them, alongside a reduced-calorie diet and increased physical activity, for adults with an initial BMI of 30 kg/m² or more, or of 27 to under 30 kg/m² with at least one weight-related comorbidity. The EMA overview (updated 26 August 2026) also lists Wegovy tablets, for adults only, in the EU, and Drugs@FDA records their US approval on 22 December 2025.

Foundayo (orforglipron)

Orforglipron is made by Eli Lilly, which also makes Mounjaro, but it is a different molecule: its UK SmPC describes an oral, high-affinity, non-peptide GLP-1 receptor agonist taken once daily. On 10 August 2026 the MHRA authorised it for weight management in adults (with the same BMI criteria as above) and for adults with insufficiently controlled type 2 diabetes, making the UK the first country in Europe to approve it. Drugs@FDA records its US approval on 1 April 2026. In the EU it was still under evaluation, with no opinion from the EMA committee meeting of 14 to 17 September 2026.

UK licensed forms and uses, checked on 5 October 2026:

Medicine	Active substance	Form	UK licensed use
Mounjaro	tirzepatide	injection, once weekly	type 2 diabetes (adults, and children aged 10 and over); weight management (adults)
Rybelsus	semaglutide	tablet, once daily	type 2 diabetes in adults only
Wegovy tablets	semaglutide	tablet, once daily	weight management in adults
Foundayo	orforglipron	tablet, once daily	weight management and type 2 diabetes in adults
"Mounjaro pills" sold online	unknown	tablet, capsule or other	none: not a licensed medicine and not Mounjaro

Main weight-management trials: Mounjaro injection and the tablets

The main published weight-management trials below were separate placebo-controlled studies with different participants, durations and methods, so their figures cannot be set side by side to rank the medicines.

• SURMOUNT-1, tirzepatide injection (Jastreboff and colleagues, New England Journal of Medicine, 2022): 2,539 adults with a BMI of 30 or more, or 27 or more with at least one weight-related complication, excluding people with diabetes. Mean weight change at week 72 was minus 15.0, 19.5 and 20.9 per cent across the three tirzepatide dose groups, against minus 3.1 per cent with placebo. Adverse events led to stopping treatment in 4.3, 7.1 and 6.2 per cent of the tirzepatide groups and 2.6 per cent of the placebo group. Supported by Eli Lilly.
• ATTAIN-1, orforglipron tablets (Wharton and colleagues, New England Journal of Medicine, 2025): 3,127 adults with obesity and without diabetes. Mean weight change at week 72 was minus 7.5, 8.4 and 11.2 per cent across the three orforglipron dose groups, against minus 2.1 per cent with placebo. Adverse events led to stopping treatment in 5.3 to 10.3 per cent of the orforglipron groups and 2.7 per cent of the placebo group. Funded by Eli Lilly.
• OASIS 4, oral semaglutide 25 mg (Wharton and colleagues, New England Journal of Medicine, 2025): 307 adults without diabetes and with a BMI of 30 or more, or 27 or more with at least one obesity-related complication. Mean weight change at week 64 was minus 13.6 per cent with oral semaglutide and minus 2.2 per cent with placebo. Gastrointestinal adverse events occurred in 74.0 per cent and 42.2 per cent respectively. Funded by Novo Nordisk.

In SURMOUNT-1 and ATTAIN-1 the most common adverse events were gastrointestinal and mostly mild to moderate. None of these results applies to products sold as Mounjaro pills.

NHS access in England

NICE recommends tirzepatide injections in two technology appraisals and, for type 2 diabetes, in its updated guideline NG28:

• TA924 (type 2 diabetes): adults whose diabetes is insufficiently controlled when triple therapy with metformin and two other oral antidiabetic drugs is ineffective, not tolerated or contraindicated, subject to BMI-related conditions.
• NG28 (type 2 diabetes in adults, updated 18 February 2026): NICE says a GLP-1 receptor agonist or tirzepatide can be considered for adults with type 2 diabetes who are living with obesity, have taken initial therapy for at least 3 months and need further medicines to reach their glucose targets, and for adults with early onset type 2 diabetes. NICE notes that work is ongoing to align TA924 with NG28.
• TA1026 (overweight and obesity): adults with an initial BMI of at least 35 kg/m² and at least one weight-related comorbidity (with a lower threshold for some ethnic backgrounds), introduced in phases as set out in NHS England's interim commissioning guidance.

The full criteria for the injection are on the Mounjaro information page. The NHS tirzepatide page says that a private prescription should be dispensed by a registered pharmacy, because some websites sell fake weight-loss medicines.

For the tablets, the MHRA said on approving Wegovy tablets (June 2026) and Foundayo (August 2026) that neither was then available on the NHS, and that decisions on NHS use would follow established processes, including an evaluation by NICE. NICE's committee first discussed orforglipron for managing overweight and obesity (ID6516) on 14 July 2026 and asked the company for more evidence; a second meeting is provisionally scheduled for 10 November 2026, with publication expected on 27 January 2027. NICE's earlier appraisal of oral semaglutide for managing overweight and obesity (ID6188) is listed as discontinued since 12 May 2025, after the company said it would not provide an evidence submission.

Mounjaro and the contraceptive pill

"Mounjaro and the pill" can also mean the contraceptive pill. The UK SmPC reports that a single dose of tirzepatide reduced blood levels of a combined oral contraceptive; it does not regard that single-dose effect as clinically relevant, but notes limited information for women with obesity or overweight. Because reduced effectiveness cannot be excluded, it advises switching to a non-oral method, or adding a barrier method, for 4 weeks after starting tirzepatide and for 4 weeks after each dose increase. The MHRA's June 2025 guidance repeats this advice for Mounjaro specifically.

The SmPC also states that tirzepatide should not be used during pregnancy and should be stopped at least 1 month before a planned pregnancy because of its long half-life.

"Mounjaro pills" sold online: fakes and illegal sellers

The MHRA describes fake medicines as illegally produced products that may contain incorrect ingredients, no active ingredients or harmful substances. Its GLP-1 guidance (updated 5 February 2026) adds that legitimate GLP-1 medicines come as pre-filled injection pens or as tablets, and that products supplied as a powder in vials, to be mixed with a liquid before injection, are not authorised. (The Mounjaro vials in the MHRA Products database are authorised as a solution for injection, not as a powder.)

On 18 June 2026 the MHRA, the Advertising Standards Authority and the GPhC jointly warned that prescription-only medicines cannot be advertised to the public, and that naming them, or using phrases such as "GLP-1 tablets", "oral GLP-1s" or "the new weight-loss tablets" in advertising, including for waiting lists, is likely to breach the advertising code.

Recent MHRA warnings and enforcement

• 24 February 2026: fake Mounjaro KwikPen 15 mg pens were found to have been dispensed by one pharmacy in Birmingham. They carried batch number D873576, a genuine number belonging to the 7.5 mg strength. Testing confirmed tirzepatide, but because the manufacturing conditions were unknown the MHRA could not confirm the contents were sterile.
• 25 February 2026: raids on two premises in Lincolnshire and Nottinghamshire, which the MHRA believed were used to make and distribute unlicensed weight-loss medicines including retatrutide and tirzepatide, seized almost 2,000 doses of unauthorised weight-loss medicines and manufacturing equipment.
• 29 May 2026: two people were arrested after a raid on a property near Northampton, believed to have been used to manufacture and distribute products including retatrutide and tirzepatide, recovered around 12,000 doses of unlicensed weight-loss medicines in what the MHRA called its largest ever seizure of such products.
• 24 July 2026: the MHRA warned that retatrutide is not authorised in the UK, so anyone selling it is doing so illegally, and that fake GLP-1 products may be contaminated with bacteria and other harmful substances.

Warning signs of a fake product or seller

The MHRA's #FakeMeds campaign lists warning signs that include:

• a prescription-only medicine offered without a prescription, or advertised with prices on a home page (illegal in the UK);
• exaggerated claims such as "100% safe", "no side effects" or "quick results";
• a web address that contains a product name, poor design or spelling mistakes, and pop-up adverts;
• payment in cryptocurrency, or a request not to name the medicine or website in the bank reference;
• no physical address;
• packs without a "UK Only" label, without the active ingredient listed or without a patient information leaflet, a missing or past expiry date, and crumbly tablets or poor-quality capsules.

One more sign is specific to this topic: Mounjaro exists only as an injection, so any product called a Mounjaro pill, tablet, capsule, drop or patch is not a licensed form of it.

How to check a pharmacy and report a seller

• All pharmacies in Great Britain, including those providing services online, must be registered with the GPhC, whose public register can be searched by pharmacy name, town or postcode, or registration number.
• For Northern Ireland, the FakeMeds site advises checking for the logo showing that a website is authorised to sell medicines online, and links to the MHRA's register of authorised online sellers.
• The MHRA runs services to check whether a website is listed as "Not Recommended" and to report a suspicious online seller of medicines, anonymously if preferred.
• GPhC guidance expects a proper consultation before any prescription-only medicine is supplied online; for weight-management medicines the prescriber must independently verify weight, height and/or BMI, not rely on a questionnaire alone.
• Suspected fake medicines and suspected side effects can be reported to the MHRA Yellow Card scheme.

UK legal position

Mounjaro KwikPen (Great Britain marketing authorisations PLGB 14895/0340 to 14895/0345) is a prescription-only medicine. Under the Human Medicines Regulations 2012 it may be sold or supplied only in accordance with a prescription from an appropriate practitioner (regulation 214), and only by a person lawfully conducting a retail pharmacy business at or from a registered pharmacy, subject to the exceptions in the Regulations (regulation 220). Regulation 284 prohibits publishing an advertisement likely to lead to the use of a prescription-only medicine.

No licensed Mounjaro pill exists, so a seller offering one cannot be supplying a licensed medicine. The MHRA has stated that selling weight-loss medicines without a prescription, for example from beauty salons or on social media, is against the law.

Side effects and warnings in the Mounjaro SmPC

The following applies to the licensed injection only; a product sold as a Mounjaro pill has no assessed safety profile. The UK SmPC lists, among others:

• Very common (1 in 10 or more in clinical studies, although some frequencies differ between trial populations): nausea, diarrhoea, vomiting, constipation, abdominal pain, decreased appetite, fatigue, and hypoglycaemia when used with a sulphonylurea or insulin.
• Common (1 in 100 to under 1 in 10): hypersensitivity reactions, dizziness, indigestion, bloating, flatulence, reflux, gallstones, hair loss, injection site reactions and increased heart rate.

On 29 January 2026 the MHRA updated product information for GLP-1 and dual GLP-1/GIP medicines about the small risk of severe acute pancreatitis, advising urgent medical attention for severe, persistent stomach pain that may spread to the back. For the tablets, the MHRA lists gastrointestinal effects such as nausea, diarrhoea, constipation and vomiting among the most common side effects of both orforglipron and semaglutide tablets. The warnings in full are summarised on the Mounjaro information page.

Frequently asked questions

Will there be a Mounjaro pill in the future?

None of the UK, EU or US regulators had approved one on 5 October 2026, and neither EMA's list of new medicines under evaluation nor its lists of extension applications contained one. Published research and ClinicalTrials.gov records show only laboratory and animal studies plus one small early-phase study of an experimental formulation, so no date can be predicted. The oral medicine Eli Lilly has had authorised, orforglipron (Foundayo), is a different substance.

Are Foundayo, Wegovy tablets or Rybelsus versions of Mounjaro?

No. Mounjaro is tirzepatide, which acts on both the GIP and GLP-1 receptors; Wegovy tablets and Rybelsus contain semaglutide and Foundayo contains orforglipron, which act on the GLP-1 receptor. Each was licensed on its own trial evidence, with its own indications, side effects and product information.

Can someone switch from Mounjaro injections to a tablet?

There is no tirzepatide tablet to switch to. Moving to a different medicine, such as a semaglutide or orforglipron tablet, is a new prescribing decision that depends on the person's condition, other medicines and each product's information. This page does not give doses or switching schedules.

Are "Mounjaro drops", patches or "natural Mounjaro" supplements real?

No. Drops, patches, sprays, gummies or supplements that borrow the Mounjaro name are not licensed forms of tirzepatide, and the unapproved compounded products described above are not Mounjaro either.

What should someone do if they have taken a "Mounjaro pill" obtained online?

The MHRA's FakeMeds advice is not to take a medicine suspected to be fake and, if one has been taken and side effects appear, to seek medical help straight away. A GP or pharmacist can advise, and the product and any side effects can be reported to the Yellow Card scheme.

Why is Mounjaro weekly while the tablets are daily?

The product information links each schedule to how long the medicine stays in the body: the Mounjaro SmPC gives tirzepatide an elimination half-life of about 5 days, enabling once-weekly administration, and the Foundayo SmPC gives orforglipron one of about 29 to 49 hours, enabling daily administration. Oral semaglutide has a half-life of about 1 week, but the Rybelsus SmPC describes low and variable absorption from each tablet and says daily administration combined with the long half-life reduces day-to-day fluctuation in exposure.

Related pages

• Mounjaro (tirzepatide) in the UK: facts, NHS rules and side effects (English)
• Mounjaro (tirzepatidă): informații (Romanian)
• Mounjaro pastile: informații (Romanian, about pills and tablets)

Sources

All sources were opened and checked on 5 October 2026.

1. Eli Lilly and Company Limited. Mounjaro 2.5 mg to 15 mg KwikPen solution for injection in pre-filled pen, Summary of Product Characteristics (text revised 29 August 2026), emc; and emc search results for tirzepatide.
2. Novo Nordisk Limited. Rybelsus 1.5 mg tablets, Summary of Product Characteristics (text revised March 2026), emc.
3. Novo Nordisk Limited. Wegovy 1.5 mg tablets, Summary of Product Characteristics (first authorised 11 June 2026), emc.
4. Eli Lilly and Company Limited. Foundayo 0.8 mg film-coated tablets, Summary of Product Characteristics (first authorised 10 August 2026), emc.
5. Medicines and Healthcare products Regulatory Agency. MHRA Products: tirzepatide.
6. European Medicines Agency. Mounjaro: EPAR medicine overview (last updated 18 August 2026); Wegovy: EPAR medicine overview (last updated 26 August 2026); First oral GLP-1 treatment for weight management (22 May 2026).
7. European Medicines Agency. Medicines for human use under evaluation, including Applications for new human medicines under evaluation, September 2026 (data extracted 4 September 2026), and the Start of procedure: extension of marketing authorisation lists (latest covering 24 July to 20 August 2026); Meeting highlights from the CHMP, 14 to 17 September 2026.
8. US Food and Drug Administration. Drugs@FDA: Mounjaro, NDA 215866; Zepbound, NDA 217806; Foundayo, NDA 220934; Wegovy tablets, NDA 218316.
9. US Food and Drug Administration. FDA's concerns with unapproved GLP-1 drugs used for weight loss (content current as of 1 October 2026).
10. Medicines and Healthcare products Regulatory Agency, GOV.UK: First GLP-1 tablet for weight loss approved in the UK (11 June 2026); UK first in Europe to authorise orforglipron for weight management and type 2 diabetes (10 August 2026); Warning on promoting newly licensed prescription-only medicines and unlicensed medicines for weight management (18 June 2026).
11. Medicines and Healthcare products Regulatory Agency, GOV.UK: Fake Mounjaro (tirzepatide) KwikPen 15mg pre-filled pens (24 February 2026); MHRA disrupts second manufacturing facility suspected to be involved in the manufacture of illegal weight loss medicines (25 February 2026); Two arrested during the MHRA's largest ever seizure of unlicensed weight loss medicines (29 May 2026); No summer shortcut for safe weight loss (24 July 2026); UK medicines regulator warns against buying weight loss medicines without a prescription this New Year (30 December 2024).
12. Medicines and Healthcare products Regulatory Agency, GOV.UK: GLP-1 medicines for weight loss and diabetes: what you need to know (updated 5 February 2026); Women on "skinny jabs" must use effective contraception, MHRA urges in latest guidance (5 June 2025); MHRA updates guidance for GLP-1 prescribers and patients (29 January 2026).
13. Medicines and Healthcare products Regulatory Agency. #FakeMeds: identify fake medicines, medical devices and suspicious websites; #FakeMeds campaign home page; Register of authorised online sellers of medicines; Check if a website is "Not Recommended" by the MHRA; Report a suspicious online seller; Yellow Card scheme.
14. General Pharmaceutical Council. Registers; Providing services online.
15. National Institute for Health and Care Excellence. Tirzepatide for managing overweight and obesity, TA1026 (published 23 December 2024, last updated 1 September 2025); Tirzepatide for treating type 2 diabetes, TA924 (published 25 October 2023, last updated 1 September 2025, last reviewed 11 May 2026); Type 2 diabetes in adults: management, NG28, further medication (last updated 18 February 2026); Orforglipron for managing overweight and obesity, ID6516, in development; NICE topic update, ID6516 (5 August 2026); Oral semaglutide for managing overweight and obesity, ID6188 (discontinued 12 May 2025).
16. NHS. Tirzepatide (page last reviewed 15 May 2026).
17. The Human Medicines Regulations 2012, regulation 214; regulation 220; regulation 284. legislation.gov.uk.
18. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205-216. PubMed 35658024.
19. Wharton S, Aronne LJ, Stefanski A, et al. Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment (ATTAIN-1). N Engl J Med. 2025;393(18):1796-1806. PubMed 40960239.
20. Wharton S, Lingvay I, Bogdanski P, et al. Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity (OASIS 4). N Engl J Med. 2025;393(11):1077-1087. PubMed 40934115.
21. US National Library of Medicine. PubMed search: tirzepatide[Title] AND oral[Title] (14 records on 5 October 2026, of which two are oral formulation studies).
22. Im S, Lee JY, Kim JE. Overcoming Gastric Barriers for Oral Peptide Delivery: QbD-Based Development of Sodium Caprate-Enabled Tirzepatide Tablets. Pharmaceutics. 2026;18(7):826. PubMed 42514904.
23. Zhang Y, Han J, Wu W, Dang B. Oral Delivery of Semaglutide and Tirzepatide Using Milk-Derived Small Extracellular Vesicles. J Extracell Biol. 2025;4(11):e70099. PubMed 41293773.
24. Belcourt J, Sapowadia A, White CM. Compounded Semaglutide and Tirzepatide Products Use Unique Formulations but Efficacy and Safety Largely Unknown. Ann Pharmacother. 2026;60(9):902-906. PubMed 41689811 (abstract).
25. US National Library of Medicine. ClinicalTrials.gov record NCT06648031 (Lexaria Bioscience, phase 1b, last updated 12 January 2026), and ClinicalTrials.gov searches for studies with a tirzepatide intervention.

This page is for information only and is not medical advice. It does not sell, offer, promote or recommend any medicine. Mounjaro is a prescription-only medicine; whether it or any other treatment is appropriate is a decision for a GP, specialist or pharmacist, who should be consulted before any medicine is started, changed or stopped. Mounjaro and KwikPen are registered trade marks of Eli Lilly; other product names belong to their owners and are used only to identify the medicines. This website has no affiliation with Eli Lilly or with any other manufacturer named on this page.